LifeSci Capital analyst Rahul Rakhit maintained a Hold rating on Better Therapeutics, Inc. (BTTX – Research Report) on May 12. The company’s shares opened today at $0.90.
Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Better Therapeutics, Inc., and Akili. According to TipRanks, Rakhit has an average return of -52.9% and a 7.50% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Better Therapeutics, Inc. with a $7.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.80 and a one-year low of $0.59. Currently, Better Therapeutics, Inc. has an average volume of 126K.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BTTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
- Is BTTX a Buy, Before Earnings?
- Galera Therapeutics expands commercial leadership team
- Fly Insider: Better Therapeutics, AMD among week’s notable insider transactions
- Better Therapeutics price target lowered to $5 from $6 at Lake Street
- Better Therapeutics directors buy $500K, CEO buys $200K in common stock
